Key result
SGLT2 inhibitors confer a ~20% risk reduction in Asian patients with HFpEF.
Why the study?
HFpEF prevalence is increasing in Asia with unique clinical characteristics and diagnostic challenges compared to Western populations.
Answers are grounded in this paper and cite their sources.
This state-of-the-art review highlights that Asian patients with HFpEF present younger with distinct 'lean-diabetic' and visceral adiposity phenotypes, requiring Asia-specific diagnostic thresholds, AI-enabled screening tools, and targeted validation of emerging cardiometabolic therapies.
Heart failure with preserved ejection fraction (HFpEF) prevalence is increasing in Asia, driven by aging populations and rising cardiometabolic risk. Asian patients with HFpEF present a decade earlier than Western counterparts, carry a disproportionate burden of diabetes, chronic kidney disease, and visceral adiposity at lower body mass index thresholds, and exhibit marked regional heterogeneity in clinical subtypes and outcomes. Diagnosis remains challenging, as algorithms derived in Western populations perform suboptimally in Asian patients, and access to echocardiography and natriuretic peptide testing is highly variable across the region. Artificial intelligence-enabled tools can bridge these diagnostic gaps. Therapeutically, sodium-glucose cotransporter 2 inhibitors demonstrate consistent benefit across Asian subgroups, whereas glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists represent important emerging options, though evidence in lean Asian subtypes remains limited. This review examines the diagnosis, clinical heterogeneity, clinical outcomes, and treatment of HFpEF across Asia, highlighting priorities for future research and quality of care.
No takes yet. Share an insight, caveat, or question.
Tromp et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Asian patients with HFpEF present a decade earlier than Western peers with high visceral adiposity and derive consistent benefit from SGLT2i.
Synapse has enriched 10 related papers. Consider them for comparative context: